Our sister site, Drug Delivery Business News, reported today that Dexcom launched its Stelo over-the-counter (OTC) CGM biosensor.
The San Diego-based company designed Stelo, a small, wearable sensor, specifically for people with type 2 diabetes who do not use insulin. Stelo features a 15-day wear based on the G7 platform. It offers a software experience tailored specifically for non-insulin users.
Dexcom said Stelo makes it easier for the target population to access CGM and offers an option for those who don’t have insurance coverage for CGM.
Get the full story at our sister site, Drug Delivery Business News.